In vivo uterine local gene delivery system using TAT-displaying bionanocapsules.
The uterus is an organ that is directly accessible via the transvaginal route, whereas drug delivery system or gene delivery system (GDS) for the uterus are very limited even in animal models. In this study, we optimized a bionanocapsule (BNC) that is a hepatitis B virus (HBV) envelope L-protein particle, of which the structurally similar particle has been used as an immunogen of a conventional HB vaccine worldwide for more than 30 years, as a local uterine GDS using a mouse model. To display various antibodies for re-targeting to different cells other than hepatic cells, the pre-S1 region of BNC was replaced with a tandem form of the protein A-derived IgG Fc-interacting region (Z domain, ZZ-BNC). To induce strong cell adhesion after the local administration into the uterine cavity, ZZ-BNC was modified with a transactivator of transcription (TAT) peptide. Gene transfer using TAT-modified ZZ-BNC is ~5,000- or 18-fold more efficient than the introduction of the same dose of naked DNAs or using the cationic liposomes, respectively. TAT-modified ZZ-BNC was rapidly eliminated from the uterus and had no effect on the pregnancy rate, litter size, or fetal growth. TAT-modified ZZ-BNC could be a useful GDS for uterine endometrial therapy via local uterine injection.